Clonexpress is a pioneering company based in Gaithersburg, MD, specializing in the development of patient-specific differentiated cell types from human primary fibroblasts and peripheral blood mononuclear cells (PBMNC) through their patented epigenetic induction technology. With a fast turnaround time of 4-6 weeks, they offer cost-effective solutions for the production of pancreatic beta cells, hepatocytes, and neuronal cells.
Furthermore, Clonexpress provides a range of cell lines for evaluation and licensing, including human fetal and adult pancreatic beta cells, dopaminergic neurons, neuronal progenitor cells, and astrocytes. They also offer human CNS primary cells and other primary cell types for in vitro research, making them a valuable resource for cell-based therapy and drug discovery.
Generated from the website
